Which 2026 Conference is Best for Policy and Regulatory Conversations?

I’ve spent the last decade watching biotech teams drop tens of thousands of dollars on registration fees and Westin St. Francis suites, only to return home with a pocketful of business cards and zero tangible progress on their regulatory or policy agenda. Let’s be clear: "networking" is a lazy objective. If you aren’t strategically positioning your firm to engage with regulators, policy makers, or capital allocators, you are just burning cash.

If your 2026 mandate is to influence FDA policy or secure the ear of officials, you need to stop treating every major event as a "must-attend." You need to understand the geography of these events, the technical backbone supporting them, and exactly who is actually in the room. ...you get the idea.

The ROI of Presence: Moving Beyond the "Vanity" Badge

Conference ROI is not measured in badge scans. Anyone can scan a badge. ROI is measured by access to decision-makers and the ability to move a regulatory hurdle or a financing round. Pretty simple.. When choosing a conference, you must weigh the opportunity cost of being in the wrong neighborhood.

For example, during JPM Week, the entire ecosystem decants into Union Square in San Francisco. It is chaotic, expensive, and logistically exhausting. If you are there for pure science, you are in the wrong place. If you are there for capital formation and high-level regulatory signaling, you are exactly where you need to be. However, many teams confuse "visibility" with "impact." If your team isn’t scheduling 1:1 meetings three months in advance, you are effectively paying for a very overpriced, crowded coffee shop.

Regulatory Access: Where to Find FDA Officials

If you are looking for FDA officials at JPM Week, they are generally in specific "safe zones." They don't linger in the hallways of the main hotel; they are sequestered in private suites. To get access, you need to move through channels that support formal partnering.

When evaluating which conference wins for policy, look at who organizes the sessions. BIO policy sessions are generally the gold standard because they are architected by the industry's primary advocacy group. Conversely, if you are looking for high-level biotech commercialization strategy, Demy-Colton events often offer a more curated, intimate environment where policy leaders are actually reachable, rather than hidden behind a phalanx of handlers.

Ask yourself this: when you register for these events, take a peek under the hood of their digital strategy. You’ll often see a CookieYes consent banner—this is a sign of a professional operation prioritizing global privacy compliance. Furthermore, if you’re tech-savvy, you’ll notice Cloudflare Bot Management cookies like __cf_bm, __cfruid, _cfuvid, and cf_clearance active on the registration portals. These aren't just technical fluff; they ensure the site stays up under heavy load and prevent automated scrapers from flooding the partner-search databases. If a conference isn't managing their digital traffic, your meeting requests are likely getting lost in the noise.

Formal Partnering: The Backbone of Efficiency

If you aren’t using partneringONE (or a similar robust scheduling system), you aren’t doing BD; you’re hoping for a miracle. Platforms like partneringONE allow you to filter for specific regulatory or policy interest tags. This is the only way to ensure your 30-minute block is spent with a target who actually cares about your filing strategy or your multiomics data roadmap.

Conference Comparison Matrix

Below is my assessment of the major 2026 players based on how they actually facilitate regulatory and policy discourse:

Event Regulatory/Policy Focus Partnering Quality Best For JPM Healthcare Week High (Exclusive/Private) Medium (Requires high-level prep) Capital formation & high-level policy BIO International Convention Very High (Public/Policy-centric) High (Global volume) Policy influence & large-scale BD Demy-Colton Events Medium-High (Curated) Very High (Intimate) Executive/Regulatory small-group strategy Informa Connect Series Medium (Varies by track) High (Technical/Functional) Specialized therapeutic/tech focuses

What I Call "Waste of Time" Events

In my decade of experience, here are the events that look good on paper but usually result in a net loss for policy teams:

The "Innovation Showcase" Gala: Unless you are pitching to a very specific pool of investors, these are just networking mixers disguised as prestige. If there isn't a pre-arranged 1:1 matching system, don't go. Large-scale "General" Biotech Summits: These are often poorly targeted. You’ll find yourself explaining your regulatory pathway to someone who doesn't even know what an IND filing is. Geographically Isolated Regional Hubs: Unless you have a specific goal in that region, avoid the temptation of a "regional tour." Focus your budget on the hubs where the regulators and capital actually meet.

The Genomics and Multiomics Trend

If your goal is to discuss the regulatory implications of AI-driven multiomics, you need to be selective. Informa Connect tends to have deep-dive tracks that are far more valuable for technical regulatory discussions than the high-level policy fluff you find at general investor conferences. If you try to pitch a complex genomics platform at a general JPM event, it will fly over the heads of the bankers. Last month, I was working with a client who wished they had known this beforehand.. Save that for a venue where the Chief Scientific Officers are the ones leading the sessions.

Final Recommendation: How to Spend Your 2026 Budget

If you have one budget for policy and bioinformant.com regulatory conversations, split it as follows:

Allocate 60% of your travel and registration budget toward BIO. The infrastructure—specifically the access to BIO policy sessions—is unmatched. Allocate 30% for JPM Week, but only if you have a formal calendar of meetings secured by December. If you can't get a suite or a firm meeting, spend that money on a specialized, smaller-format Demy-Colton salon instead. Allocate 10% for specialized technical summits (likely through Informa Connect) that deal specifically with the multiomics or regulatory hurdles relevant to your current product pipeline.

Stop chasing the badge scan. Stop assuming that "networking" equates to growth. Get into the room where the policy is actually written, use the technical partnering tools to ensure your meetings are functional, and stop paying for "visibility" that doesn't advance your bottom line.